^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TYK2 inhibitor

    Associations

    News

    Trials
    2d
    A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis (clinicaltrials.gov)
    P3, N=606, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting
    Enrollment closed
    3d
    Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis (clinicaltrials.gov)
    P3, N=1182, Not yet recruiting, Takeda
    New P3 trial
    3d
    First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD) (clinicaltrials.gov)
    P1/2, N=35, Recruiting, First Affiliated Hospital of Zhejiang University
    New P1/2 trial
    3d
    Deucravacitinib for the Treatment of Palmoplantar Pustulosis (clinicaltrials.gov)
    P4, N=3, Terminated, Brigham and Women's Hospital | N=18 --> 3 | Trial completion date: Jun 2026 --> Jan 2025 | Recruiting --> Terminated; Sponsor terminated funding
    Enrollment change • Trial completion date • Trial termination
    7d
    COMBo: Deucravacitinib-TNF Combination Therapy for Difficult-to-Control Psoriatic Disease (clinicaltrials.gov)
    P4, N=128, Not yet recruiting, University of Texas Southwestern Medical Center
    New P4 trial
    9d
    An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function (clinicaltrials.gov)
    P1, N=16, Completed, Alumis Inc | Recruiting --> Completed | N=48 --> 16 | Trial completion date: Dec 2025 --> Aug 2025 | Trial primary completion date: Dec 2025 --> Aug 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    10d
    Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov)
    P3, N=390, Recruiting, InventisBio Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    11d
    Healthy Volunteer Study (clinicaltrials.gov)
    P1, N=36, Recruiting, InventisBio Co., Ltd
    New P1 trial
    16d
    POETYK SLE-1: A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
    P3, N=516, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting | Trial completion date: Dec 2027 --> Nov 2028 | Trial primary completion date: Dec 2025 --> Oct 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    17d
    POETYK SLE-2: A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (clinicaltrials.gov)
    P3, N=513, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting | Trial completion date: Dec 2027 --> Nov 2028 | Trial primary completion date: Dec 2025 --> Oct 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    18d
    Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Bristol-Myers Squibb
    New trial
    23d
    A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis (clinicaltrials.gov)
    P3, N=110, Not yet recruiting, Takeda
    New P3 trial